* BridgeBio Pharma Inc is expected to show a fall in quarterly revenue when it reports results on November 11 (estimated) for the period ending September 30 2024
* The Palo Alto California-based company is expected to report a 8.1% decrease in revenue to $3.762 million from $4.09 million a year ago, according to the mean estimate from 12 analysts, based on LSEG data.
* LSEG's mean analyst estimate for BridgeBio Pharma Inc is for a loss of 98 cents per share.
* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 15 "strong buy" or "buy," 2 "hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in the last three months.
* Wall Street's median 12-month price target for BridgeBio Pharma Inc is $46.00, above its last closing price of $25.88.
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER STARMINESM LSEG IBES ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT ESTIMATE MET, SE %
E® MISSED
Jun. 30 2024 -1.07 -1.06 -0.39 Beat 63.3
Mar. 31 2024 -0.87 -0.76 -0.20 Beat 73.8
Dec. 31 2023 -0.90 -0.91 -0.96 Missed -5.4
Sep. 30 2023 -0.82 -0.82 -1.08 Missed -32.4
Jun. -0.82 -0.83 -0.98 Missed -17.6
30 2023
Mar. 31 2023 -0.85 -0.83 -0.92 Missed -10.7
Dec. 31 2022 -0.84 -0.85 -0.92 Missed -8
Sep. 30 2022 -0.99 -0.99 -0.93 Beat 6.5
This summary was machine generated November 8 at 17:07 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
Comments